Healthcare

Neurizon® Therapeutics Limited (ASX:NUZ & NUZOA), a clinical-stage biotechnology company focused on treating neurodegenerative disorders, has announced new rodent pharmacokinetic (PK) data demonstrating that its lead compound NUZ-001 and its primary active metabolite, NUZ-001 Sulfone, successfully cross the blood-brain barrier (BBB). This achievement marks …

Neuren Pharmaceuticals Ltd (ASX:NEU), a biotechnology company focused on therapies for childhood neurodevelopmental disorders, has garnered significant support from market analysts following a record-setting financial performance in FY24 and promising guidance for 2025.

Recce Pharmaceuticals (ASX:RCE; OTC:RECEF) has announced a non-dilutive debt facility of up to AUD 30 million (US$20 million) from global investment firm Avenue Capital Group, a move that marks a pivotal step in supporting the company’s clinical and commercial objectives.

CSL (ASX:CSL; USOTC:CSLLY) has announced that the U.S. Food and Drug Administration (FDA) has approved ANDEMBRY® for immediate launch across the United States. ANDEMBRY® is now officially authorized as a preventive treatment for hereditary angioedema (HAE) in adult and pediatric patients aged 12 years …

Monash IVF Group Ltd (ASX:MVF), an Australian reproductive healthcare company, continues to attract positive sentiment from market analysts. Despite recent operational and leadership challenges, the company has maintained a consensus BUY recommendation, with analysts forecasting significant upside for its share price.

Cochlear Ltd (ASX:COH), a global leader in hearing implants, has garnered positive sentiment from analysts even as it revised its financial guidance downward for FY25. The latest endorsement came from Jefferies analyst David Stanton, who issued aBUY ratingon 12 June 2025.

Cochlear Ltd (ASX:COH) shares fell significantly on Thursday, trading 9% lower in the morning session at $246.52. The sell-off was triggered by a downgrade in the company’s earnings guidance for the financial year ending 30 June 2025.